This trend was also significant in p16+ oropharyngeal cancer (proportion of SOX2High in pT1 and -2 vs. pT3 and -4: 81.8% vs. 16.7%, p = 0.001, Fisher’s exact test) but not significant in the p16− group (proportion of SOX2High in pT1 and -2 vs. pT3 and -4: 71.4% vs. 46.2%, p = 0.169, Fisher’s exact test) (Table 2). The gene discussed is CDKN2A; the disease is oropharynx cancer.